Summit Therapeutics Inc [SMMT] stock is trading at $22.62, up 6.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SMMT shares have gain 6.35% over the last week, with a monthly amount glided 27.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on July 01, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $30. Previously, Leerink Partners started tracking the stock with Underperform rating on June 11, 2025, and set its price target to $12. On March 26, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $35 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Evercore ISI initiated its recommendation with a Outperform and recommended $30 as its price target on March 12, 2025. Goldman started tracking with a Buy rating for this stock on February 28, 2025, and assigned it a price target of $42. In a note dated January 08, 2025, Truist initiated an Buy rating and provided a target price of $35 on this stock.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $6.78 and $36.91 over the past year. Currently, Wall Street analysts expect the stock to reach $38.25 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $22.62 at the most recent close of the market. An investor can expect a potential return of 69.1% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.7 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.58 points at the first support level, and at 20.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.25, and for the 2nd resistance point, it is at 23.88.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 10.63. As well, the Quick Ratio is 10.63, while the Cash Ratio is 6.06.
